EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q2 2023 Earnings Call Transcript August 2, 2023 8:30 AM ET

Company Participants

George Elston - Chief Financial Officer

Dr. Jay Duker - President, and Chief Executive Officer

Conference Call Participants

Tyler Van Buren - Cowen

Yatin Suneja - Guggenheim

Jennifer Kim - Cantor Fitzgerald

Colleen Kusy - Baird

Daniel Catalin - Chardan

Sean Kim - Jones Trading

I-Eh Jen - Laidlaw & Co

Chaitanya Gollakota - H.C. Wainwright

Operator

Good morning. My name is [indiscernible] and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Second Quarter 2023 Financial Results and Recent Corporate Development Conference Call. There will be a question and answer session to follow at the completion of the prepared remarks. Please be advised that this call is being recorded at the Company's request.

I would now like to turn the call over to George Elston, Chief Financial Officer of EyePoint Pharmaceuticals.

George Elston

Thank you, and thank you all for joining us on today's conference call to discuss EyePoint Pharmaceuticals' second quarter 2023 financial results and recent corporate developments. With me today is Dr. Jay Duker, President and Chief Executive Officer. Jay will begin with a review of recent corporate updates and discuss Phase II clinical trials for EYP-1901, I will close with commentary on our second quarter 2023 financial results and we will then open the call for your questions.

Earlier this morning, we issued a press release detailing our financial results and recent operational developments. A copy of the release can be found in the Investor Relations tab on the corporate website, www.eyepointpharma.com.

Before we begin our formal comments, I'll remind you that various remarks we will make today constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. These include statements about our future expectations, clinical developments and regulatory matters and time lines, the potential success of our products and product candidates, financial projections, and our plans and prospects.

Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent annual report on Form 10-K, which is on file with the SEC and in other filings that we may make with the SEC in the future. Any forward-looking statements represent our views as of today only. While we may elect to update those forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.